ISPOR's Value Assessment Stakeholder Conference showed its Special Task Force still reaching for clarification around the subject, writes Ansis Helmanis.
Ansis Helmanis
Advertisement
Ansis Helmanis is a former FDA official and founder of RegLink Associates.
Articles by Ansis Helmanis
Harvey Bale, Jr., MD, former Director-General, IFPMA
Jane Henney, MD, Former FDA Commissioner
Advertisement
Latest Updated Articles
IP: Securing a Global Consensus—Can Industry Do It Again?Published: October 1st 2011 | Updated:
Jane Henney: Lessons from the FDA Front LinePublished: October 1st 2011 | Updated:
- ISPOR Task Force Grapples with Value Questions
Published: September 28th 2016 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Bob Mauch: Strengthening the Chain
2
Novo Nordisk Stock Reacts to Recent Board Changes
3
The Long-Term Outlook for MFN Pricing: Far-Reaching Issues and Considerations
4
What Impact will DTC Programs Have on Prescription Drug Prices?
5
